Open AccessLiquid biopsy assay for pulmonary adenocarcinoma using supernatants from core‐needle biopsy specimens
Author(s) -
Kong Fanlei,
Li Yuanming,
Guo Runqi,
Yang Li,
Di Jing,
He Lei,
Wang Zheng,
Liu Dongge,
Li Xiaoguang
Publication year - 2022
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.14461
Subject(s) - medicine , concordance , biopsy , genotyping , adenocarcinoma , lung cancer , pathology , genomic dna , liquid biopsy , lung , dna , microbiology and biotechnology , cancer , genotype , gene , biology , genetics
Background Genomic testing is the cornerstone of the treatment of patients with non‐small‐cell lung cancer. However, comprehensive molecular testing of small specimens may be inadequate due to limited tissue. Liquid biopsy has emerged as a new method of genotyping. In this study, we evaluate the feasibility of using supernatants from core needle biopsy samples of lung adenocarcinoma for genomic testing. Methods Core needle biopsy specimens and their supernatants were collected from patients ( n = 48) with lung adenocarcinoma. Genomic testing results of the supernatant samples were compared with results derived from paired tissue samples from the same patient. Result All 48 supernatant samples yield adequate cell‐free DNA, but the concentration of cell‐free RNA did not meet the criteria for analysis. The concordance rate between the genomic testing results of supernatants and the corresponding tissue samples was 95.8% (kappa = 0.899). The coincidence rate of detectable mutations at the DNA level in the supernatants was up to 100%. Conclusion Core needle biopsy supernatants can provide a valuable specimen source for genotyping pulmonary adenocarcinoma. However, the method of preserving and extracting RNA from supernatant specimens needs further improvement.